These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 24719121)

  • 1. Unrecognized kinetics of serum testosterone: impact on short-term androgen deprivation therapy for prostate cancer.
    Koo KC; Lee DH; Kim KH; Lee SH; Hong CH; Hong SJ; Chung BH
    Yonsei Med J; 2014 May; 55(3):570-5. PubMed ID: 24719121
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kinetics of serum androgen normalization and factors associated with testosterone reserve after limited androgen deprivation therapy for nonmetastatic prostate cancer.
    Gulley JL; Aragon-Ching JB; Steinberg SM; Hussain MH; Sartor O; Higano CS; Petrylak DP; Chatta GS; Arlen PM; Figg WD; Dahut WL
    J Urol; 2008 Oct; 180(4):1432-7; discussion 1437. PubMed ID: 18710748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
    Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
    Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
    Nascimento B; Miranda EP; Jenkins LC; Benfante N; Schofield EA; Mulhall JP
    J Sex Med; 2019 Jun; 16(6):872-879. PubMed ID: 31080102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chemical castration on sex offenders in relation to the kinetics of serum testosterone recovery: implications for dosing schedule.
    Koo KC; Ahn JH; Hong SJ; Lee JW; Chung BH
    J Sex Med; 2014 May; 11(5):1316-24. PubMed ID: 24571582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
    Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
    BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Continuous vs. intermittent androgen deprivation therapy for metastatic prostate cancer.
    Langenhuijsen JF; Badhauser D; Schaaf B; Kiemeney LA; Witjes JA; Mulders PF
    Urol Oncol; 2013 Jul; 31(5):549-56. PubMed ID: 21561791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recovery of Serum Testosterone Levels and Sexual Function in Patients Treated With Short-term Luteinizing Hormone-releasing Hormone Antagonist as a Neoadjuvant Therapy Before External Radiotherapy for Intermediate-risk Prostate Cancer: Preliminary Prospective Study.
    Inoue T; Mizowaki T; Kabata D; Shintani A; Terada N; Yamasaki T; Negoro H; Kobayashi T; Nakamura K; Inokuchi H; Ogawa O
    Clin Genitourin Cancer; 2018 Apr; 16(2):135-141.e1. PubMed ID: 29051056
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-like growth factor-1 is associated with regulation of the luteinizing hormone production in men receiving androgen deprivation therapy with gonadotropin-releasing hormone analogues for localized prostate cancer.
    Hara N; Takizawa I; Isahaya E; Nishiyama T; Hoshii T; Ishizaki F; Takahashi K
    Urol Oncol; 2012 Sep; 30(5):596-601. PubMed ID: 21458314
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individual variation of hormonal recovery after cessation of luteinizing hormone-releasing hormone agonist therapy in men receiving long-term medical castration therapy for prostate cancer.
    Kobayashi T; Nishizawa K; Mitsumori K
    Scand J Urol Nephrol; 2006; 40(3):198-203. PubMed ID: 16809259
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer.
    Boccon-Gibod L; Albers P; Morote J; van Poppel H; de la Rosette J; Villers A; Malmberg A; Neijber A; Montorsi F
    Eur Urol; 2014 Oct; 66(4):655-63. PubMed ID: 24954791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone levels in patients with metastatic prostate cancer treated with luteinizing hormone-releasing hormone therapy: prognostic significance?
    Perachino M; Cavalli V; Bravi F
    BJU Int; 2010 Mar; 105(5):648-51. PubMed ID: 19747358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetics of testosterone recovery in clinically localized prostate cancer patients treated with radical prostatectomy and subsequent short-term adjuvant androgen deprivation therapy.
    Dai B; Qu YY; Kong YY; Ye DW; Yao XD; Zhang SL; Zhang HL; Yang WY
    Asian J Androl; 2013 Jul; 15(4):466-70. PubMed ID: 23708460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer.
    Gagliano-Jucá T; Travison TG; Nguyen PL; Kantoff PW; Taplin ME; Kibel AS; Manley R; Hally K; Bearup R; Beleva YM; Huang G; Edwards RR; Basaria S
    J Pain Symptom Manage; 2018 Feb; 55(2):307-317.e1. PubMed ID: 28941963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of testosterone-guided androgen deprivation therapy in management of prostate cancer.
    Niraula S; Templeton AJ; Vera-Badillo FE; Joshua AM; Sridhar SS; Cheung PW; Yip PM; Dodd A; Nugent Z; Tannock IF
    Prostate; 2016 Feb; 76(2):235-42. PubMed ID: 26768279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone recovery in the off-treatment time in prostate cancer patients undergoing intermittent androgen deprivation therapy.
    Tunn UW; Canepa G; Kochanowsky A; Kienle E
    Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):296-302. PubMed ID: 22733160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with testosterone recovery after androgen deprivation therapy in patients with prostate cancer.
    Nam W; Choi SY; Yoo SJ; Ryu J; Lee J; Kyung YS; Han JH; You D; Jeong IG; Hong JH; Ahn H; Kim CS
    Investig Clin Urol; 2018 Jan; 59(1):18-24. PubMed ID: 29333510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
    Strum SB; Scholz MC; McDermed JE
    Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum testosterone level predicts the effective time of androgen deprivation therapy in metastatic prostate cancer patients.
    Wang Y; Dai B; Ye DW
    Asian J Androl; 2017; 19(2):178-183. PubMed ID: 26975487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen deprivation therapy duration is significantly associated with Testosterone recovery in Japanese patients with prostate cancer.
    Arai M; Kosaka T; Yasumizu Y; Takeda T; Matsumoto K; Oya M
    Int J Urol; 2023 Feb; 30(2):235-239. PubMed ID: 36375076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.